Clinical trial Recruiting at 2 sites Interventional Ages 18 and up

Monitoring postoperative complications in cancer patients with a smart system

Official title: Postoperative Complications in Cancer Patients Monitored With Intelligent Continuous Monitoring System Versus Standard of Care - a Randomized Clinical Trial

Run by Copenhagen University Hospital, Rigshospitalet · NCT06269198 · Data updated 2026-11-12

This study is testing a smart monitoring system that sends alerts about vital signs to see if it helps high-risk cancer patients recover better after surgery compared to regular monitoring.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment504 (estimated)
SponsorCopenhagen University Hospital, Rigshospitalet
Academic / other
Drugs / interventionschemotherapy
Locations3 sites (Copenhagen, Other (Non US) and 2 other locations)
StatusRecruiting
StartedOctober 31, 2023
Main results expectedApril 1, 2025
Study endsApril 1, 2027
Registry record updatedJanuary 15, 2025
Trial IDNCT06269198 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients undergoing elective major abdominal surgery for cancer with an expected postoperative stay of at least two days.

Probably not a fit

Patients who are unable to cooperate with study procedures or have cognitive impairments may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of an intelligent continuous monitoring system that provides automatic vital sign alerts compared to routine monitoring alone in high-risk postoperative cancer patients. It is a multicenter randomized controlled trial where patients will be assigned to either an intervention group receiving active alerts or a control group with blinded data collection. The study will assess the severity of complications, frequency of serious adverse events, mortality, length of hospital stay, and delays in planned chemotherapy within 30 days post-surgery.

Why it matters

Potential benefit: If successful, this approach could significantly reduce the severity of postoperative complications in cancer patients, leading to improved recovery outcomes.

How similar studies have gone: Other studies utilizing continuous monitoring systems have shown promising results, suggesting that this approach could be effective.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Admission for elective major abdominal (gastrointestinal, gynecological, or urological) surgery with the primary aim of radical surgery/removing suspected cancer tissue.
* At least two expected postoperative admission days
* Laparotomy or laparoscopy procedure estimated to last more than 2 hours.
* Co-enrolment of patients in other studies is acceptable but in studies involving interventions which potentially will affect the continuous monitoring of vital signs and/or the primary or secondary outcomes, an assessment of whether these patients can be co-enrolled in the WARD-RCT should be conferred with the WARD RCT steering committee.

Exclusion Criteria:

* Patient expected not to cooperate with study procedures
* Allergy to study materials (silicone, plaster)
* Impaired cognitive function (in uncertain cases assessed by a Mini Mental State Examination score \< 24). (Protocol Appendix E)
* Patients with a pacemaker or Implantable Cardioverter Defibrillator (ICD) device
* Inability to give informed consent
* Patients with planned hyperthermic intraperitoneal chemotherapy (HIPEC) procedure or two-stage resections (two-stage hepatectomy, two-stage resection of malignant colorectal obstructions, etc.)

Where it's running

  • Copenhagen University hospital - Rigshospitalet
    Copenhagen, Other (Non US), Denmark
    Recruiting
  • Bispebjerg Hospital
    Copenhagen, Other (Non US), Denmark
    Recruiting
  • Hvidovre Hospital
    Hvidovre, Other (Non US), Denmark
    Not yet recruiting

Study contacts

  • Principal investigator: Jesper Mølgaard, PhD — Copenhagen University Hospital, Rigshospitalet
  • Study coordinator: Jesper Mølgaard, PhD
  • Email: moelgaard.jesper@gmail.com
  • Phone: +4535453545

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.